Scientists make 'exciting' advancement in certain breast cancer drugs

Two new drugs for advanced HER2-positive breast cancer were tested in separate studies, and scientists say they've made progress in the development of new tr...

Posted: Dec 17, 2019 8:29 AM

Two new drugs for advanced HER2-positive breast cancer were tested in separate studies, and scientists say they've made progress in the development of new treatment options.

This type of breast cancer tests positive for higher levels of a protein called HER2.

One study, published in the New England Journal of Medicine last week, found that adding the experimental drug tucatinib to a chemotherapy regimen consisting of the drugs trastuzumab and capecitabine could improve survival for adults with advanced HER2-positive metastatic breast cancer.

The other study, also published in the New England Journal of Medicine last week, found that the experimental drug conjugate called trastuzumab deruxtecan was able to substantially reduce tumor activity in patients with HER2-positive metastatic breast cancer.

"Both studies are evaluating new drugs for HER2-positive breast cancer, which represents about 15% to 20% of all breast cancers," said Dr. Eric Winer, chief of the division of breast oncology at Dana-Farber Cancer Institute in Boston and professor of medicine at Harvard Medical School, who was the senior author of the tucatinib study.

"What's so exciting is we have developed multiple new drugs for HER2-positive breast cancer -- we have new drugs for all subtypes of breast cancer -- but the changes are most dramatic in the setting of HER2-positive breast cancer," Winer said.

"It is the single area in breast cancer where we have made the most dramatic progress and continue to," he said. "For individuals with advanced breast cancer we can individualize therapy more than in the past; it is no longer one size fits all."

The tucatinib study: 'It was pretty well tolerated'

The tucatinib study included 613 patients who previously underwent chemotherapy for HER2-positive metastatic breast cancer by taking the drugs trastuzumab, pertuzumab and trastuzumab emtansine -- but that treatment approach had stopped working for the patients.

For the study, the patients were randomly assigned to either the drug tucatinib or a placebo and received chemotherapy with the drugs trastuzumab and capecitabine.

The researchers found that in the first year of treatment, 33.1% of patients in the tucatinib group did not see their cancer progress compared with 12.3% of patients in the placebo group.

The researchers also found that overall survival two years after starting treatment was 44.9% among patients in the tucatinib group and 26.6% among those in the placebo group.

Side effects of the tucatinib treatment that emerged in the study included the risks of diarrhea and elevated levels of an enzyme in the body called aminotransferase.

"But in general it was pretty well tolerated," Winer said.

Next year, the biotechnology company Seattle Genetics, which develops tucatinib, plans to submit a new drug application to the US Food and Drug Administration and an application to the European Medicines Agency with the goal of bringing this new medicine to the public, Dr. Roger Dansey, chief medical officer at the company, said in a press release on Wednesday.

"Continued innovation to bring new therapies for the treatment of metastatic HER2-positive breast cancer is urgently needed, and we are encouraged by the impressive clinical activity demonstrated with the addition of tucatinib to trastuzumab and capecitabine," he said in part.

The trastuzumab deruxtecan study: 'I am cautiously optimistic'

The trastuzumab deruxtecan study included 184 patients who had already undergone multiple prior treatments for HER2-positive breast cancer. The patients were given the recommended dose of trastuzumab deruxtecan at 5.4 mg per kilogram of body weight.

The researchers found that the patients saw no further progression of their cancer for a median of 16.4 months and that the cancer in 60.9% of the patients shrunk by at least 50% in response to the treatment. However, the treatment came with some side effects, including nausea, myelosuppression -- the decline of bone marrow activity -- and interstitial lung disease.

Overall, "it is rare that a drug has effects on women heavily pretreated," said Dr. Otis Brawley, Bloomberg Distinguished Professor of oncology and epidemiology at Johns Hopkins University, who was not involved in the new study.

"I am cautiously optimistic," he said, but added that more research is needed to determine whether trastuzumab deruxtecan could help patients live longer.

Dr. Ian Krop, a principal investigator of the study and associate chief of the division of breast oncology at Dana-Farber Cancer Institute in Boston, called the research results "striking" in a press release on Wednesday.

"These results are particularly striking as trastuzumab deruxtecan prompted a high level of durable tumor reduction among patients, the majority of whom had exhausted most if not all standard therapies for HER2-metastatic breast cancer," he said. "We are excited by these results and their potential to help patients with this advanced stage of breast cancer."

Huntsville
Few Clouds
38° wxIcon
Hi: 52° Lo: 30°
Feels Like: 38°
Florence
Clear
43° wxIcon
Hi: 57° Lo: 32°
Feels Like: 39°
Fayetteville
Clear
39° wxIcon
Hi: 52° Lo: 28°
Feels Like: 39°
Decatur
Clear
41° wxIcon
Hi: 52° Lo: 29°
Feels Like: 36°
Scottsboro
Clear
45° wxIcon
Hi: 55° Lo: 30°
Feels Like: 45°
WAAY Radar
WAAY WAAY-TV Cam
WAAY Temperatures

Alabama Coronavirus Cases

Cases: 264199

Reported Deaths: 3831
CountyCasesDeaths
Jefferson35310515
Mobile20626372
Madison14521153
Tuscaloosa13897173
Montgomery12844246
Shelby1127878
Baldwin9501138
Lee807167
Morgan740555
Etowah704870
Marshall695358
Calhoun6939126
Houston559140
DeKalb521843
Cullman490650
St. Clair466557
Limestone462446
Lauderdale452257
Elmore440070
Walker3914112
Talladega386157
Jackson373523
Colbert347948
Blount323146
Autauga294542
Franklin265534
Coffee260023
Dale247355
Dallas236832
Chilton235445
Covington234834
Russell23433
Escambia208832
Tallapoosa192692
Chambers189154
Clarke165422
Pike165215
Marion150236
Winston146325
Lawrence139936
Pickens129720
Geneva12929
Marengo127824
Bibb127038
Barbour121729
Butler121142
Cherokee108224
Randolph108022
Fayette102216
Hale102132
Clay95527
Washington94222
Henry9097
Monroe85311
Lowndes82930
Cleburne80914
Macon77522
Crenshaw73830
Lamar7348
Conecuh73215
Bullock71120
Perry7037
Wilcox65918
Sumter60122
Greene45818
Choctaw43620
Coosa3854
Out of AL00
Unassigned00

Tennessee Coronavirus Cases

Cases: 392608

Reported Deaths: 4876
CountyCasesDeaths
Shelby50255694
Davidson45276434
Knox20582164
Rutherford19202173
Hamilton18414169
Williamson1223687
Sumner10700144
Out of TN919354
Wilson812788
Montgomery723887
Sullivan7128114
Washington6651118
Maury639675
Blount617665
Putnam616285
Bradley577538
Madison5671116
Unassigned537729
Sevier531738
Robertson410957
Tipton389939
Hamblen375263
Gibson344672
Greene338074
Dyer333552
Anderson327232
Coffee307943
Dickson307839
Carter300763
Bedford298134
Lawrence293738
McMinn284257
Obion279855
Cumberland274138
Roane257833
Warren253919
Jefferson249535
Loudon246921
Fayette238840
Monroe235046
Hardeman230938
Franklin228340
Weakley227836
Hawkins215936
Lauderdale214423
Wayne198611
Henderson198334
Macon193630
Trousdale192912
White190919
Rhea188836
Carroll187336
Hardin186529
Marshall186122
Lincoln178620
Cocke174430
Cheatham172017
Haywood169530
Campbell168524
Henry165322
Giles158951
Overton158237
Smith151820
Johnson147923
McNairy144434
Fentress127524
DeKalb126725
Hickman125819
Bledsoe12275
Marion121219
Lake12077
Crockett119329
Scott11778
Grainger109918
Chester106923
Claiborne99510
Decatur98313
Unicoi96928
Benton88816
Cannon8254
Lewis81916
Grundy81514
Morgan8097
Union7715
Humphreys7709
Jackson72811
Polk71515
Stewart63618
Houston60720
Sequatchie5965
Clay57819
Meigs53912
Perry51522
Moore4212
Pickett40714
Van Buren3893
Hancock2004

Community Events